Does ALPELISIB Cause Second primary malignancy? 19 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 19 reports of Second primary malignancy have been filed in association with ALPELISIB (PIQRAY). This represents 0.2% of all adverse event reports for ALPELISIB.
19
Reports of Second primary malignancy with ALPELISIB
0.2%
of all ALPELISIB reports
2
Deaths
4
Hospitalizations
How Dangerous Is Second primary malignancy From ALPELISIB?
Of the 19 reports, 2 (10.5%) resulted in death, 4 (21.1%) required hospitalization, and 1 (5.3%) were considered life-threatening.
Is Second primary malignancy Listed in the Official Label?
Yes, Second primary malignancy is listed as a known adverse reaction in the official FDA drug label for ALPELISIB.
What Other Side Effects Does ALPELISIB Cause?
Hyperglycaemia (1,575)
Rash (1,393)
Diarrhoea (1,336)
Blood glucose increased (1,105)
Death (921)
Nausea (860)
Fatigue (817)
Decreased appetite (546)
Weight decreased (508)
Malignant neoplasm progression (497)
What Other Drugs Cause Second primary malignancy?
CYCLOPHOSPHAMIDE (1,247)
DOXORUBICIN (1,151)
VINCRISTINE (908)
IMATINIB (763)
PALBOCICLIB (658)
RITUXIMAB (646)
RUXOLITINIB (611)
ETOPOSIDE (573)
PREDNISONE (517)
OCTREOTIDE (496)
Which ALPELISIB Alternatives Have Lower Second primary malignancy Risk?
ALPELISIB vs ALPHA.-LIPOIC ACID
ALPELISIB vs ALPHA.-TOCOPHEROL
ALPELISIB vs ALPHA.-TOCOPHEROL, D-
ALPELISIB vs ALPHA.-TOCOPHEROL, DL-
ALPELISIB vs ALPHA.1-PROTEINASE INHIBITOR HUMAN